Trial Profile
A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulations in Children With Central Precocious Puberty
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary)
- Indications Precocious puberty
- Focus Registrational; Therapeutic Use
- Sponsors Abbott Laboratories; TAP Pharmaceutical Products
- 01 May 2012 Primary endpoint 'Clinical-response-rate' has been met.
- 05 Mar 2012 New trial record